Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Gennova Biopharmaceuticals Limited currently manages 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners, providing a variety of perspectives on the company's patent applications. Nathan W Schlientz is the busiest examiner for the portfolio, overseeing 1 pending office action. The portfolio also spans 4 distinct art units.
For a practitioner, the distribution of 4 pending office actions across different examiners suggests that the portfolio is not dependent on a single individual's interpretation. The focus on the Biotechnology & Pharmaceuticals technology area indicates a specialized technical direction. Because 4 distinct art units are involved, the company may encounter varying examination standards, which requires a coordinated prosecution approach.
Managing the distinct examiners requires a proactive approach to ensure that responses are aligned with the overall strategic goals of the company. Practitioners should analyze the allowance rates and prosecution timelines for each assigned examiner to better predict the outcomes for these pending matters. This approach helps in navigating the complexities of the biotechnology patent landscape where examiner discretion can be significant. Maintaining a unified legal position across different examiners is essential for a strong intellectual property portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHLIENTZ, NATHAN W | 1 | 41.3% | -18.9% |
| BOATENG, AFUA BAMFOAA | 1 | 46.6% | +64.4% |
| ESPINOSA, CLAUDIA EDILMA | 1 | 50.9% | +57.7% |
| XU, QING | 1 | 50.9% | +55.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18578881 | RNA ADSORBED ONTO LIPID NANO-EMULSION PARTICLES AND ITS FORMULATIONS | SCHLIENTZ, NATHAN W | 30d overdue |
| 17414790 | A LYOPHILIZED COMPOSITION OF PEGASPARGASE | ESPINOSA, CLAUDIA EDILMA | — |
| 17058960 | PROCESS FOR PRODUCTION OF RECOMBINANT TNK-TPA BY PACKED-BED PERFUSION SYSTEM | XU, QING | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17631863 | OPTHALMIC COMPOSITION OF BEVACIZUMAB | BOATENG, AFUA BAMFOAA | — |
| 17414790 | A LYOPHILIZED COMPOSITION OF PEGASPARGASE | ESPINOSA, CLAUDIA EDILMA | — |
| 17058960 | PROCESS FOR PRODUCTION OF RECOMBINANT TNK-TPA BY PACKED-BED PERFUSION SYSTEM | XU, QING | — |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| 1617 | 1 |
| 1654 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18578881 | RNA ADSORBED ONTO LIPID NANO-EMULSION PARTICLES AND ITS FORMULATIONS | SCHLIENTZ, NATHAN W | 1616 | §102§103§112 | Final Rejection | 30d overdue | Pending | Jan 12, 2024 |
| 17631863 | OPTHALMIC COMPOSITION OF BEVACIZUMAB | BOATENG, AFUA BAMFOAA | 1617 | §103 | Non-Final OA | — | Pending | Jan 31, 2022 |
| 17414790 | A LYOPHILIZED COMPOSITION OF PEGASPARGASE | ESPINOSA, CLAUDIA EDILMA | 1654 | §103§112 | Non-Final OA | — | Pending | Jun 16, 2021 |
| 17058960 | PROCESS FOR PRODUCTION OF RECOMBINANT TNK-TPA BY PACKED-BED PERFUSION SYSTEM | XU, QING | 1656 | §103§112 | Final Rejection | — | Pending | Nov 25, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial